Suchergebnisse - %22Ritonavir%22

PubPharm (84)

1

Applications of peptide-functionalized or unfunctionalized selenium nanoparticles for the passivation of SARS-CoV-2 variants and the respiratory syncytial virus (RSV)

enthalten in: Colloids and surfaces. B, Biointerfaces | 2024

von Nahhas, A. | Webster, T.

2

Exploring diverse reactive warheads for the design of SARS-CoV-2 main protease inhibitors

enthalten in: European journal of medicinal chemistry | 2023

von Tan, B. | Sacco, M. | Tan, H. | +5

3

A yeast-based system to study SARS-CoV-2 Mpro structure and to identify nirmatrelvir resistant mutations

enthalten in: PLoS pathogens | 2023

von Ou, J. | Lewandowski, E. | Hu, Y. | +12

UpdateOf: bioRxiv. 2022 Aug 08;:. - PMID 35982672

4

Integrative Approach to Dissect the Drug Resistance Mechanism of the H172Y Mutation of SARS-CoV-2 Main Protease

enthalten in: Journal of chemical information and modeling | 2023

von Clayton, J. | de Oliveira, V. | Ibrahim, M. | +5

UpdateOf: bioRxiv. 2023 Mar 06;:. - PMID 35982652

5

AI-Driven Discovery of SARS-CoV-2 Main Protease Fragment-like Inhibitors with Antiviral Activity In Vitro

enthalten in: Journal of chemical information and modeling | 2023

von Saramago, L. | Santana, M. | Gomes, B. | +13

6

SARS-CoV-2 main protease inhibitors : What is moving in the field of peptides and peptidomimetics?

enthalten in: Journal of peptide science : an official publication of the European Peptide Society | 2023

von Algar-Lizana, S. | Bonache, M. | González-Muñiz, R.

7

A Novel Y-Shaped, S-O-N-O-S-Bridged Cross-Link between Three Residues C22, C44, and K61 Is Frequently Observed in the SARS-CoV-2 Main Protease

enthalten in: ACS chemical biology | 2023

von Yang, K. | Blankenship, L. | Kuo, S. | +7

8

Impact of Drug Exposure on Resistance Selection Following Artemether-Lumefantrine Treatment for Malaria in Children With and Without HIV in Uganda

enthalten in: Clinical pharmacology and therapeutics | 2023

von Kay, K. | Goodwin, J. | Ehrlich, H. | +13

9

The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor In Vitro and Confer Resistance To Nirmatrelvir

enthalten in: mBio | 2023

von Jochmans, D. | Liu, C. | Donckers, K. | +22

10

SARS-CoV-2 Main Protease Drug Design, Assay Development, and Drug Resistance Studies

enthalten in: Accounts of chemical research | 2023

von Tan, B. | Joyce, R. | Tan, H. | +2

1
2
3
4
5
6
7
8
9
Nächster »
[9]